Severe acute pancreatitis secondary to the use of immune checkpoint inhibitors

Authors

  • Lázaro Arango Molano Jefe del programa de Gastroenterología de la Universidad de Caldas, Manizales, Colombia; Coordinador del comité de endosonografía, Sociedad Interamericana de Endoscopia Digestiva, Buenos Aires, Argentina; Gastroenterólogo Clínico Quirúrgico, Universidad de Caldas, Manizales, Colombia; Gastroenterólogo de Unión de Cirujanos, Grupo Zentria, Manizales, Colombia. https://orcid.org/0000-0001-5197-2326
  • Andrés Sánchez Gil Gastroenterólogo Clínico Quirúrgico, Universidad de Caldas, Manizales, Colombia; Gastroenterólogo de Unión de Cirujanos, Grupo Zentria, Manizales, Colombia. https://orcid.org/0000-0002-1159-5316
  • Fabian Puentes Manosalva Gastroenterólogo Clínico Quirúrgico, Universidad de Caldas, Manizales, Colombia; Gastroenterólogo de Unión de Cirujanos, Grupo Zentria, Manizales, Colombia. https://orcid.org/0000-0002-6769-0048
  • Karla Patricia Gutiérrez de la Peña Fellow de Gastroenterología Clínico-Quirúrgica, Universidad de Caldas, Manizales, Colombia. https://orcid.org/0009-0002-3596-5497
  • Herney Solarte Pineda Fellow de Gastroenterología Clínico-Quirúrgica, Universidad de Caldas, Manizales, Colombia. https://orcid.org/0009-0007-6998-4991
  • Santiago Salazar Ochoa Fellow de Gastroenterología Clínico-Quirúrgica, Universidad de Caldas, Manizales, Colombia. https://orcid.org/0000-0002-7343-3080

DOI:

https://doi.org/10.47892/rgp.2026.461.2062

Keywords:

Immune Checkpoint Inhibitors, Acute Pancreatitis, Necrosis, Endosonographic, Colombia

Abstract

ICI-induced pancreatic injury is a rare subtype of immune-related adverse events. Although it is a relatively rare event and most patients who present it are asymptomatic, a subgroup of patients may present clinical and radiological manifestations typical of severe acute pancreatitis, with long-term sequelae of endo- and exocrine pancreatic function. Advanced age, the combination of ICIs, preexisting autoimmune diseases, and tumor type have been described as risk factors for developing this pathology. We report the case of a patient with metastatic renal cancer, a history of partial pancreatectomy, treated with checkpoint inhibitors, who developed severe acute pancreatitis with the formation of walled-off pancreatic necrosis after the third application. Other etiologies were ruled out; multidisciplinary management and endoscopic management with endosonographic drainage with apposition stent were provided, with a successful outcome and clinical recovery of the patient.

Downloads

Download data is not yet available.

References

Mederos MA, Reber HA, Girgis MD. Incorrect Positive Predictive Values Reported. JAMA. 2021;325(23):2405. doi: 10.1001/jama.2021.5789.

Saini J, Marino D, Badalov N, Vugelman M, Tenner S. DrugInduced Acute Pancreatitis: An Evidence-Based Classification (Revised). Clin Transl Gastroenterol. 2023;14(8):e00621. doi: 10.14309/ctg.0000000000000621.

Abu-Sbeih H, Tang T, Lu Y, Thirumurthi S, Altan M, Jazaeri AA, Dadu R, Coronel E, Wang Y. Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury. J Immunother Cancer. 2019;7(1):31. doi: 10.1186/ s40425-019-0502-7.

Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med. 2018;378(2):158-168. doi: 10.1056/NEJMra1703481.

Lin HF, Liao KF, Chang CM, Lin CL, Lai SW. Association of use of selective serotonin reuptake inhibitors with risk of acute pancreatitis: a case-control study in Taiwan. Eur J Clin Pharmacol. 2017;73(12):1615-1621. doi: 10.1007/s00228-017- 2328-x.

Ljung R, Rück C, Mattsson F, Bexelius TS, Lagergren J, Lindblad M. Selective serotonin reuptake inhibitors and the risk of acute pancreatitis: a Swedish population-based case-control study. J Clin Psychopharmacol. 2012;32(3):336-40. doi: 10.1097/ JCP.0b013e318253d71a.

Nørgaard M, Jacobsen J, Gasse C, Pedersen L, Mortensen PB, Sørensen HT. Selective serotonin reuptake inhibitors and risk of acute pancreatitis: a population-based case-control study. J Clin Psychopharmacol. 2007;27(3):259-62. doi: 10.1097/ JCP.0b013e318058a9c3.

Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, et al. Management of Immunotherapy-Related Toxicities, Version 1.2019. J Natl Compr Canc Netw. 2019;17(3):255-289. doi: 10.6004/jnccn.2019.0013.

Kwok G, Yau TC, Chiu JW, Tse E, Kwong YL. Pembrolizumab (Keytruda). Hum Vaccin Immunother. 2016;12(11):2777-2789. doi: 10.1080/21645515.2016.1199310.

George J, Bajaj D, Sankaramangalam K, Yoo JW, Joshi NS, Gettinger S, et al. Incidence of pancreatitis with the use of immune checkpoint inhibitors (ICI) in advanced cancers: A systematic review and meta-analysis. Pancreatology. 2019;19(4):587-594. doi: 10.1016/j.pan.2019.04.015.

Nwankwo OC, Lara-Salazar FM, Lara-Salazar S, Abdulrahim AO, Chijioke I, Singh J, et al. Immune Checkpoint Inhibitors in Cancer Treatment and Incidence of Pancreatitis. Cureus. 2024;16(8):e68043. doi: 10.7759/cureus.68043.

Rogers BB, Cuddahy T, Zawislak C. Management of Acute Pancreatitis Associated With Checkpoint Inhibitors. J Adv Pract Oncol. 2020;11(1):49-62. doi: 10.6004/jadpro.2020.11.1.3.

Published

03/29/2026

How to Cite

1.
Arango Molano L, Sánchez Gil A, Puentes Manosalva F, Gutiérrez de la Peña KP, Solarte Pineda H, Salazar Ochoa S. Severe acute pancreatitis secondary to the use of immune checkpoint inhibitors. Rev Gastroenterol Peru [nternet]. 2026 Mar. 29 [cited 2026 Mar. 30];46(1):82-7. vailable from: https://revistagastroperu.com/index.php/rgp/article/view/2062

Issue

Section

REPORTES DE CASOS

Most read articles by the same author(s)